New hope for advanced breast cancer: targeted drug combo under study
NCT ID NCT03959891
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 27 times
Summary
This early-phase study tests whether adding an AKT inhibitor (ipatasertib) to standard hormone therapy, with or without a CDK 4/6 inhibitor, is safe and can shrink tumors in women with metastatic hormone receptor-positive breast cancer. About 77 participants will receive the combination to see how well it controls the disease. The goal is to manage the cancer, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.